UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Today's Latest Price: $21.64 USD
Updated Oct 20 4:00pm
Add URGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
URGN Stock Summary
- URGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than only 4.45% of US-listed equities with positive expected earnings growth.
- With a price/sales ratio of 1,358.73, UroGen Pharma Ltd has a higher such ratio than 99.52% of stocks in our set.
- As for revenue growth, note that URGN's revenue has grown 1,966.67% over the past 12 months; that beats the revenue growth of 99.46% of US companies in our set.
- Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are NYMX, OCX, PTN, PRTA, and CRMD.
- Visit URGN's SEC page to see the company's official filings. To visit the company's web site, go to www.urogen.com.
URGN Stock Price Chart Interactive Chart >
URGN Price/Volume Stats
| Current price | $21.64 | 52-week high | $35.21 |
| Prev. close | $22.95 | 52-week low | $13.12 |
| Day low | $21.32 | Volume | 122,500 |
| Day high | $23.11 | Avg. volume | 192,661 |
| 50-day MA | $21.65 | Dividend yield | N/A |
| 200-day MA | $24.35 | Market Cap | 452.21M |
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
Loading social stream, please wait...